Standard BioTools Inc. (LAB) Income Statement
LAB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLAB revenue and net income
Where LAB's revenue goes
2025Each bar shows an amount and its share of revenue. LAB kept −87.8% of revenue as net income.
LAB profit margins
LAB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −51.1% | −4.5% | −9.2% | −2.9% |
| Gross profit | −49.5% | +4.7% | −12.6% | −4.6% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LAB quarterly EPS vs estimates
Standard BioTools beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 3, 2026 (estimate $-0.01).
LAB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.3M | $174.4M | $106.3M | $97.9M | $130.6M | $138.1M | $117.2M | $113.0M | $101.9M | $104.4M |
| Cost of revenue | $42.8M | $90.2M | $55.9M | $60.9M | $53.3M | $54.8M | $53.0M | $51.3M | $50.0M | $46.0M |
| Gross profit | $42.5M | $84.3M | $50.5M | $37.1M | $77.3M | $83.3M | $64.3M | $61.6M | $52.0M | $58.4M |
| Research & development | $26.0M | $62.4M | $25.9M | $37.4M | $37.9M | $36.5M | $31.6M | $30.0M | $30.8M | $38.4M |
| Sales, general & admin | $109.9M | $156.6M | $98.9M | $114.8M | $98.9M | $97.9M | $84.5M | $79.8M | $79.5M | $93.2M |
| Total operating expenses | $135.8M | $259.5M | $127.0M | $153.3M | $144.7M | $134.4M | $116.1M | $109.8M | $110.3M | $131.6M |
| Operating income | −$93.3M | −$175.2M | −$76.6M | −$116.2M | −$67.5M | −$51.0M | −$51.8M | −$48.2M | −$58.4M | −$73.2M |
| Interest income | $9.2M | $20.2M | $5.6M | $64.4M | $3.8M | $3.6M | $4.3M | $13.9M | $5.8M | $5.8M |
| Interest expense | $26,000 | $3.3M | $4.6M | $4.3M | $3.8M | $3.6M | $4.3M | $13.9M | $5.8M | $5.8M |
| Income before taxes | −$96.7M | −$138.3M | −$74.2M | −$192.9M | −$63.7M | −$54.1M | −$66.7M | −$61.4M | −$63.8M | −$80.2M |
| Income taxes | −$37.9M | $573,000 | $452,000 | −$2.8M | −$4.4M | −$1.1M | −$1.9M | −$2.4M | −$3.3M | −$4.2M |
| Net income | −$74.9M | −$138.9M | −$74.7M | −$190.1M | −$59.2M | −$53.0M | −$64.8M | −$59.0M | −$60.5M | −$76.0M |
| EBITDA | −$85.7M | −$118.1M | −$54.5M | −$173.6M | −$44.3M | −$34.6M | −$46.6M | −$31.0M | −$39.7M | −$56.4M |
| EPS (diluted) | −$0.06 | −$0.40 | −$0.74 | −$1.21 | −$0.46 | −$0.30 | −$0.36 | −$0.63 | −$1.04 | −$1.44 |
| Gross margin | 49.9% | 48.3% | 47.4% | 37.8% | 59.2% | 60.3% | 54.8% | 54.6% | 51.0% | 55.9% |
| Operating margin | −109.3% | −100.5% | −72.0% | −118.6% | −51.7% | −36.9% | −44.2% | −42.6% | −57.3% | −70.1% |
| Net margin | −87.8% | −79.6% | −70.2% | −194.1% | −45.4% | −38.4% | −55.3% | −52.2% | −59.4% | −72.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.1M | $21.1M | $23.8M | $19.6M | $21.8M | $20.2M | $46.7M | $45.0M | $22.5M | $45.5M | $28.2M | $25.4M |
| Cost of revenue | $9.6M | $9.8M | $13.6M | $10.1M | $11.1M | $9.2M | $24.8M | $21.7M | $12.1M | $21.4M | $14.8M | $14.2M |
| Gross profit | $10.5M | $11.3M | $10.2M | $9.5M | $10.6M | $11.0M | $21.9M | $23.3M | $10.4M | $24.2M | $13.4M | $11.2M |
| Research & development | $2.0M | $2.1M | $7.8M | $6.4M | $6.2M | $5.4M | $14.1M | $13.2M | $7.2M | $16.0M | $6.9M | $6.4M |
| Sales, general & admin | $16.4M | $18.6M | $25.3M | $26.6M | $28.1M | $38.7M | $37.6M | $34.4M | $37.7M | $46.9M | $21.4M | $22.3M |
| Total operating expenses | $35.9M | $20.7M | $32.2M | $33.0M | $34.3M | $35.3M | $54.7M | $55.0M | $40.6M | $84.4M | $34.7M | $32.3M |
| Operating income | −$25.4M | −$9.4M | −$21.9M | −$23.5M | −$23.7M | −$24.2M | −$32.8M | −$31.7M | −$30.3M | −$60.2M | −$21.4M | −$21.2M |
| Interest income | — | $3.5M | $1.7M | $2.1M | $2.5M | $2.9M | $3.3M | $3.9M | $4.4M | $5.2M | — | $1.2M |
| Interest expense | — | — | $5,000 | $10,000 | $9,000 | $2,000 | $3.3M | — | $858,000 | $1.0M | $1.1M | $1.2M |
| Income before taxes | −$21.4M | −$14.6M | −$22.0M | −$32.9M | −$18.3M | −$23.5M | −$33.8M | −$26.8M | −$25.4M | −$32.0M | −$19.9M | −$20.9M |
| Income taxes | $90,000 | $11,000 | −$35.9M | −$1.2M | −$609,000 | −$119,000 | $272,000 | $118,000 | $39,000 | $128,000 | −$162,000 | $50,000 |
| Net income | −$26.8M | −$45.2M | $19.3M | −$34.7M | −$33.5M | −$26.0M | −$34.1M | −$26.9M | −$45.7M | −$32.2M | −$19.8M | −$21.0M |
| EBITDA | −$28.1M | −$13.2M | −$20.7M | −$31.4M | −$16.3M | −$19.3M | −$26.0M | −$20.4M | −$20.7M | −$25.8M | −$14.9M | −$13.5M |
| EPS (diluted) | −$0.05 | −$0.02 | $0.07 | −$0.04 | −$0.04 | −$0.05 | −$0.05 | −$0.03 | −$0.08 | −$0.24 | −$0.25 | −$0.14 |
| Gross margin | 52.4% | 53.5% | 43.0% | 48.5% | 48.8% | 54.6% | 46.9% | 51.7% | 46.1% | 53.1% | 47.4% | 44.0% |
| Operating margin | −126.3% | −44.5% | −92.1% | −120.0% | −108.9% | −119.7% | −70.2% | −70.5% | −134.5% | −132.2% | −75.9% | −83.5% |
| Net margin | −133.1% | −213.9% | 81.0% | −177.4% | −153.7% | −128.7% | −72.9% | −59.9% | −203.3% | −70.6% | −70.2% | −82.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LAB's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LAB financial results
In fiscal year 2025 (ended December 31, 2025), Standard BioTools reported revenue of $85.3 million, down 51.1% from the year before. It had a net loss of $74.9 million, a net profit margin of −87.8%. Diluted earnings per share came to −$0.06. Over five years revenue grew at an average rate of −9.2% a year.
See the LAB stock overview for the latest quote and news, or the LAB chart for price history and technical indicators.
LAB income statement FAQ
What is Standard BioTools's annual revenue?
Standard BioTools reported total revenue of $85.3 million for fiscal year 2025, which ended on December 31, 2025. That was down 51.1% from $174.4 million the previous year.
Is Standard BioTools profitable?
No. Standard BioTools reported a net loss of $74.9 million in fiscal 2025, a net profit margin of −87.8%; its operating margin was −109.3%.
What is Standard BioTools's gross margin?
Standard BioTools's gross margin was 49.9% in fiscal 2025: for every $100 of revenue, Standard BioTools kept $50 after the direct cost of its products and services.
How much does Standard BioTools spend on research and development?
Standard BioTools spent $26.0 million on research and development in fiscal 2025, 30.5% of revenue.
How fast is Standard BioTools growing?
Revenue grew −9.2% a year on average over the last five fiscal years, from $138.1 million to $85.3 million.
What are Standard BioTools's earnings per share?
Standard BioTools earned $-0.06 per diluted share in fiscal 2025, compared with $-0.40 a year earlier.
When will Standard BioTools report its next earnings?
Standard BioTools is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does Standard BioTools's fiscal year end?
Standard BioTools's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.